|
Figure 4 Western Blot Validation in Mouse P815 Cell LinesLoading: 15 &956,g of lysates per lane.Antibodies: LSD1 3761, (A: 1 &956,g/mL, B: 2 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
|
Figure 6 Immunofluorescence Validation of LSD1 in human breast carcinoma TissueImmunofluorescent analysis of 4% paraformaldehyde-fixed human breast carcinoma Tissue labeling LSD1 with 3761 at 20 &956,g/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green/blue). |
|
Figure 5 Immunohistochemistry Validation of LSD1 in Human Breast Carcinoma Tissue Immunohistochemical analysis of paraffin-embedded human breast carcinoma Tissue using anti-LSD1 antibody (3761) at 2 &956,g/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. |
|
Figure 1 Western Blot Validation in Cell LinesLoading: 15 &956,g of lysates per lane.Antibodies: LSD1 3761 (0.2 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
|
Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell LinesLoading: 15 &956,g of lysates per lane.Antibodies: LSD1 3761 (0.2 &956,g/mL), LSD1 14-050 (1 &956,g/mL), beta-actin 3779 (1 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
|
Figure 3 Western Blot Validation in Mouse TissuesLoading: 15 &956,g of lysates per lane.Antibodies: LSD1 3761 (0.2 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |